SecBot SecBot
SECBOTREPLAY Home › Report › PFE

PFE · A Special Master in the District of Delaware denied GSK's motion to…

PFIZER INC · COURT-RULING filed Jun 15, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 2/10

COURT-RULING filed Jun 15, 2026 at 20:00 ET

A Special Master in the District of Delaware denied GSK's motion to limit Pfizer/BioNTech and Moderna to a combined 10 hours of deposition time for two key inventor witnesses in related patent infringement cases against PFE and MRNA. The ruling preserves each defendant group's full 7-hour deposition entitlement per witness, meaning PFE/BioNTech can conduct independent, uncoordinated depositions of Drs. Geall and Mandl without sharing time with Moderna. This is a procedural discovery ruling with no financial exposure, it keeps the litigation on its current schedule and does not change the merits of the patent claims against PFE.

  • Special Master denied GSK's motion to limit PBNT and Moderna to a combined 10 hours of deposition time for two key inventor witnesses (Drs. Geall and Mandl).
  • Each defendant group retains the full 7-hour deposition entitlement per witness under Fed. R. Civ. P. 30(d)(1).
  • The ruling does not require PBNT and Moderna to coordinate questioning or attend each other's depositions.
  • Fact discovery closes July 29, 2026, the ruling keeps the existing schedule intact.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access